Ghisallo Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Ghisallo Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.88M	Buy	+500,000	New	+$4.34M	0.1%	159

Other funds holding KPTI

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Ghisallo Capital Management's KPTI Position: Q2 2026 in Review

Ghisallo Capital Management opened a new position in Karyopharm Therapeutics (KPTI) in Q2 2026: 500,000 shares worth $4.88M. The stake represents 0.1% of the portfolio and ranks #159 among its holdings.

64 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Ghisallo Capital Management held 500,000 shares of Karyopharm Therapeutics worth $4.88M as of Q2 2026.
Karyopharm Therapeutics was a new Ghisallo Capital Management position in Q2 2026.
Karyopharm Therapeutics made up 0.1% of Ghisallo Capital Management's portfolio in Q2 2026, its #159 holding.
64 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Ghisallo Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.